Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ZC3H12A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ZC3H12A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ZC3H12A_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ZC3H12A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ZC3H12A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ZC3H12A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00105069 | Prostate | BPH | regulation of autophagy | 86/3107 | 317/18723 | 1.29e-06 | 2.24e-05 | 86 |
GO:004312210 | Prostate | BPH | regulation of I-kappaB kinase/NF-kappaB signaling | 71/3107 | 249/18723 | 1.55e-06 | 2.64e-05 | 71 |
GO:004682410 | Prostate | BPH | positive regulation of nucleocytoplasmic transport | 26/3107 | 62/18723 | 2.06e-06 | 3.40e-05 | 26 |
GO:004259410 | Prostate | BPH | response to starvation | 59/3107 | 197/18723 | 2.10e-06 | 3.45e-05 | 59 |
GO:003109810 | Prostate | BPH | stress-activated protein kinase signaling cascade | 70/3107 | 247/18723 | 2.32e-06 | 3.79e-05 | 70 |
GO:00071628 | Prostate | BPH | negative regulation of cell adhesion | 82/3107 | 303/18723 | 2.51e-06 | 4.04e-05 | 82 |
GO:005140310 | Prostate | BPH | stress-activated MAPK cascade | 68/3107 | 239/18723 | 2.77e-06 | 4.41e-05 | 68 |
GO:004670010 | Prostate | BPH | heterocycle catabolic process | 111/3107 | 445/18723 | 3.58e-06 | 5.54e-05 | 111 |
GO:004427014 | Prostate | BPH | cellular nitrogen compound catabolic process | 112/3107 | 451/18723 | 4.04e-06 | 6.12e-05 | 112 |
GO:00466857 | Prostate | BPH | response to arsenic-containing substance | 17/3107 | 33/18723 | 4.14e-06 | 6.25e-05 | 17 |
GO:00171484 | Prostate | BPH | negative regulation of translation | 68/3107 | 245/18723 | 7.01e-06 | 1.01e-04 | 68 |
GO:001943910 | Prostate | BPH | aromatic compound catabolic process | 113/3107 | 467/18723 | 1.30e-05 | 1.72e-04 | 113 |
GO:00511708 | Prostate | BPH | import into nucleus | 48/3107 | 159/18723 | 1.42e-05 | 1.85e-04 | 48 |
GO:002240716 | Prostate | BPH | regulation of cell-cell adhesion | 109/3107 | 448/18723 | 1.43e-05 | 1.85e-04 | 109 |
GO:00712437 | Prostate | BPH | cellular response to arsenic-containing substance | 12/3107 | 20/18723 | 1.44e-05 | 1.87e-04 | 12 |
GO:190136110 | Prostate | BPH | organic cyclic compound catabolic process | 118/3107 | 495/18723 | 1.75e-05 | 2.17e-04 | 118 |
GO:003461216 | Prostate | BPH | response to tumor necrosis factor | 68/3107 | 253/18723 | 2.22e-05 | 2.67e-04 | 68 |
GO:00435429 | Prostate | BPH | endothelial cell migration | 73/3107 | 279/18723 | 3.03e-05 | 3.46e-04 | 73 |
GO:00105086 | Prostate | BPH | positive regulation of autophagy | 39/3107 | 124/18723 | 3.17e-05 | 3.60e-04 | 39 |
GO:00066068 | Prostate | BPH | protein import into nucleus | 46/3107 | 155/18723 | 3.42e-05 | 3.82e-04 | 46 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZC3H12A | SNV | Missense_Mutation | novel | c.925N>C | p.Gly309Arg | p.G309R | Q5D1E8 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
ZC3H12A | SNV | Missense_Mutation | novel | c.698N>T | p.Ala233Val | p.A233V | Q5D1E8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A2FE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
ZC3H12A | SNV | Missense_Mutation | novel | c.754N>A | p.Glu252Lys | p.E252K | Q5D1E8 | protein_coding | deleterious(0.02) | probably_damaging(0.954) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
ZC3H12A | SNV | Missense_Mutation | | c.1711N>A | p.Ala571Thr | p.A571T | Q5D1E8 | protein_coding | tolerated(0.33) | benign(0.044) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZC3H12A | SNV | Missense_Mutation | | c.1792N>G | p.Ser598Gly | p.S598G | Q5D1E8 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ZC3H12A | SNV | Missense_Mutation | | c.1684N>A | p.Gly562Ser | p.G562S | Q5D1E8 | protein_coding | deleterious(0.04) | benign(0.219) | TCGA-BH-A0E0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
ZC3H12A | SNV | Missense_Mutation | | c.1457N>G | p.Ala486Gly | p.A486G | Q5D1E8 | protein_coding | tolerated(0.57) | benign(0.001) | TCGA-E9-A245-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ZC3H12A | SNV | Missense_Mutation | novel | c.574N>G | p.Pro192Ala | p.P192A | Q5D1E8 | protein_coding | tolerated(0.25) | probably_damaging(0.99) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
ZC3H12A | SNV | Missense_Mutation | novel | c.725C>T | p.Ser242Phe | p.S242F | Q5D1E8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZC3H12A | insertion | Nonsense_Mutation | novel | c.971_972insTTGCTAAGAGTCCCCTAGCATCTTCCTGATGGTCTTTCTGCCTT | p.Glu324AspfsTer3 | p.E324Dfs*3 | Q5D1E8 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |